Day one of the RSV window: what changed, who disagrees, and the clinic question that matters

Today, 1 October 2026, is day one of the infant RSV antibody window in most of the continental United States. That date is not a slogan. It is the start of the months CDC uses for nirsevimab and clesrovimab in most states: October through March.

This is the week’s most important parent-facing development. Not because RSV is new, but because the first week of October is when birth hospitals and pediatric offices either give the dose, defer it, or let the conversation die at “call your pediatrician.”

Not medical advice. Not a prescription. Eligibility and product choice belong to the clinic.

## Background

RSV has been the leading cause of infant hospitalization in the United States. CDC still cites tens of thousands of hospitalizations each year in children under five.

Two tools now sit on the same calendar:

- A maternal vaccine (Pfizer’s Abrysvo) given at 32–36 weeks of pregnancy. Protection for the baby is strongest when birth is at least 14 days after that shot.
- A long-acting infant antibody given as a shot to the baby: nirsevimab or clesrovimab for first-season infants under 8 months. Protection starts immediately and is intended to last the season (about five months).

Most babies should not need both. The infant antibody is for babies whose mother did not get the pregnancy vaccine, whose date is unknown, or who were born within 14 days of that dose.

Palivizumab, the older monthly product, is gone after 31 December 2025. That is why the new single-dose products are the whole conversation this winter.

## What changed this week

Three things stacked on 1 October.

First, the seasonal door opened. CDC guidance says infants born during the window should get the antibody within one week of birth, ideally before leaving the birth hospital. Infants born earlier who are still under 8 months and entering a first season should get it shortly before the season — meaning now.

Second, first-season and second-season are still being mixed up in parent groups. First season (under 8 months): either licensed infant antibody. Second season (8–19 months, high-risk only): nirsevimab only. Clesrovimab is not the second-season product. AAP’s 2026–2027 statement also widened which high-risk toddlers qualify for that second-season nirsevimab dose.

Third, real-world numbers from other systems keep arriving. Israel reported about 130,000 infants already protected and pointed to European data showing an 83% drop in RSV hospitalization risk after antibody programs. Austria reported 74% fewer RSV hospital admissions in the first year of life compared with 2023–24, with a smaller drop in the second year of life. Those are other countries and other seasons. They are not a US guarantee. They are why clinics are treating October as an operations problem, not a theory problem.

## Competing viewpoints

The parent who wants the shot today. For a first-season baby with no documented maternal dose, waiting “until the pediatrician next month” is the gap the guidance is trying to close. Birth-hospital administration exists because RSV does not wait for the two-week checkup.

The parent who already got Abrysvo on time. If birth was 14 or more days after that dose, the infant antibody is usually not added. That is the “most infants will not need both” line. Pushing for a second product “just in case” is a clinic decision, not a default.

The parent of an 8–19 month old who was sick last winter. Second-season protection is not universal. It is high-risk only, and it is nirsevimab, often as two 100 mg injections (200 mg total). If the office only stocked clesrovimab for newborns, that toddler still needs a different product.

The supply-skeptic. Last winters had allocation fights. This briefing cannot promise every nursery has both products on the shelf tonight. That is why the useful question is not “do you believe in RSV shots?” It is “which product is on the shelf today, and if neither, when is the follow-up?”

The “is this even a vaccine?” debate. It is not a classic vaccine. It is passive immunization: ready-made antibodies. That distinction matters for counseling and for people who refuse anything labeled vaccine. It does not change the CDC recommendation for eligible infants.

## What to watch next

- Whether birth hospitals in your state are giving the dose before discharge this week, or handing out a “call your pediatrician” card.
- Which product is actually in the fridge: nirsevimab, clesrovimab, or neither.
- Second-season nirsevimab access for the expanded high-risk 8–19 month group AAP described for 2026–2027.
- Local RSV activity. The window is calendar-based in most of the continental US; Alaska, tropical regions, and off-cycle seasons have different timing.
- Leftover recalled gear in the same hospital bag you packed for the birth: Love to Dream LTD-SM23 sleep machines, Melissa & Doug Target fire-truck boards with a loose hose port, Skip Hop Elmo teethers that were frozen.

## The clinic question

Write this down before the visit:

- Baby date of birth and weight.
- Maternal RSV vaccine: date given / not given / unknown.
- If given: was birth 14 or more days later?
- First season or second season?
- Product given today, or reason deferred, plus the follow-up date.

That is the whole job for day one of the window.

Companion briefing: /blog/parent-briefing-rsv-day-one-clinic-ask-recalls-1-october-2026-late

Sources: CDC RSV immunization guidance for infants and young children; AAP 2026–2027 RSV prevention recommendations; CPSC recall notices dated 3, 17, and 24 September 2026.